Dr. Saag has received consulting fees from Novartis, Ardea Biosciences, and Savient (less than $10,000 each) and has received research funding from Takeda.
Developing a provisional definition of flare in patients with established gout
Article first published online: 26 APR 2012
Copyright © 2012 by the American College of Rheumatology
Arthritis & Rheumatism
Volume 64, Issue 5, pages 1508–1517, May 2012
How to Cite
Gaffo, A. L., Schumacher, H. R., Saag, K. G., Taylor, W. J., Dinnella, J., Outman, R., Chen, L., Dalbeth, N., Sivera, F., Vázquez-Mellado, J., Chou, C.-T., Zeng, X., Perez-Ruiz, F., Kowalski, S. C., Goldenstein-Schainberg, C., Chen, L., Bardin, T. and Singh, J. A. (2012), Developing a provisional definition of flare in patients with established gout. Arthritis & Rheumatism, 64: 1508–1517. doi: 10.1002/art.33483
- Issue published online: 26 APR 2012
- Article first published online: 26 APR 2012
- Accepted manuscript online: 14 NOV 2011 11:47AM EST
- Manuscript Accepted: 9 NOV 2011
- Manuscript Received: 21 SEP 2010
- American College of Rheumatology
- European League Against Rheumatism
Additional Supporting Information may be found in the online version of this article.
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.